TGF-β1 and TNF-α differentially regulate Twist1 mediated resistance towards BRAF/MEK inhibition in melanoma

Pigment Cell and Melanoma Research

Volumn 26, Issue 6, 2013, Pages 912-916

  Menon, Dinoop R ^a   Wels, Christian ^a   Bonyadi Rad, Ehsan ^a   Joshi, Shripad ^a   Knausz, Heike ^a   Lade Keller, Johanne ^b   Brandner, Johanna M ^c   Schaider, Helmut ^a,d  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b The Department of Pathology ^*  (Denmark)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

BRAF; Drug resistance; TGF 1; TNF ; Twist1

Indexed keywords

PROTEIN; TRAMETINIB; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TWIST1 PROTEIN; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTICLE; CELL DEATH; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PHENOTYPE;

BRAF; DRUG RESISTANCE; TGF-Β1; TNF-Α; TWIST1;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA; TWIST TRANSCRIPTION FACTOR;

EID: 84886292330     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12139     Document Type: Article

References (20)

1. Charles, K.A., Kulbe, H., Soper, R. et al. (2009). The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J. Clin. Invest. 119, 3011-3023.
2. Cheng, G.Z., Zhang, W.Z., Sun, M., Wang, Q., Coppola, D., Mansour, M., Xu, L.M., Costanzo, C., Cheng, J.Q., and Wang, L.H. (2008). Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J. Biol. Chem. 283, 14665-14673.
3. Decker, T., and Kovarik, P. (2000). Serine phosphorylation of STATs. Oncogene 19, 2628-2637.
4. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
5. Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
6. Gray-Schopfer, V.C., Karasarides, M., Hayward, R., and Marais, R. (2007). Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res. 67, 122-129.
7. Johannessen, C.M., Boehm, J.S., Kim, S.Y. et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
8. Koefinger, P., Wels, C., Joshi, S., Damm, S., Steinbauer, E., Beham-Schmid, C., Frank, S., Bergler, H., and Schaider, H. (2011). The cadherin switch in melanoma instigated by HGF is mediated through epithelial-mesenchymal transition regulators. Pigment Cell Melanoma Res 24, 382-385.
9. Kwok, W.K., Ling, M.T., Lee, T.W. et al. (2005). Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 65, 5153-5162.
10. Lazar-Molnar, E., Hegyesi, H., Toth, S., and Falus, A. (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12, 547-554.
11. Li, Q.Q., Xu, J.D., Wang, W.J., Cao, X.X., Chen, Q., Tang, F., Chen, Z.Q., Liu, X.P., and Xu, Z.D. (2009). Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin. Cancer Res. 15, 2657-2665.
12. Li, C.W., Xia, W., Huo, L. et al. (2012). Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res. 72, 1290-1300.
13. Nazarian, R., Shi, H., Wang, Q. et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
14. Popivanova, B.K., Kitamura, K., Wu, Y., Kondo, T., Kagaya, T., Kaneko, S., Oshima, M., Fujii, C., and Mukaida, N. (2008). Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118, 560-570.
15. Starsichova, A., Lincova, E., Pernicova, Z., Kozubik, A., and Soucek, K. (2010). TGF-beta1 suppresses IL-6-induced STAT3 activation through regulation of Jak2 expression in prostate epithelial cells. Cell. Signal. 22, 1734-1744.
16. Straussman, R., Morikawa, T., Shee, K. et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504.
17. Venkatasubbarao, K., Choudary, A., and Freeman, J.W. (2005). Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res. 65, 2861-2871.
18. Villanueva, J., Vultur, A., Lee, J.T. et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
19. Weiss, M.B., Abel, E.V., Mayberry, M.M., Basile, K.J., Berger, A.C., and Aplin, A.E. (2012). TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res. 72, 6382-6392.
20. Wilson, T.R., Fridlyand, J., Yan, Y. et al. (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509.